Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer
Status:
Unknown status
Trial end date:
2021-08-09
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well eribulin mesylate works in treating patients with
advanced or recurrent cervical cancer. Drugs used in chemotherapy, such as eribulin mesylate,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing